48 results on '"Bhasin, Manoj K."'
Search Results
2. Supplementary Figure FS2 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
3. Supplementary Figure FS2 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
4. Supplementary Table TS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
5. Data from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
6. Supplementary Figure FS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
7. Data from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
8. Supplementary Figure FS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
9. Supplementary Figure 3 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
10. Supplementary Figure 7 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
11. Supplementary Figure 5 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
12. Supplementary Figure 6 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
13. Supplementary Figure 8 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
14. Supplementary Table 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
15. Supplementary Figure Legends from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
16. Data from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
17. Supplementary Figure 5 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
18. Supplementary Figure 7 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
19. Supplementary Figure 2 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
20. Supplementary Figure 9 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
21. Supplementary Figure 3 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
22. Supplementary Figure 2 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
23. Supplementary Figure 9 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
24. Supplementary Figure Legends from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
25. Supplementary Figure 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
26. Data from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
27. Supplementary Figure 4 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
28. Supplementary Figure 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
29. Supplementary Methods from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
30. Supplementary Table 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
31. Supplementary Figure 6 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
32. Supplementary Figure 4 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
33. Supplementary Methods from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
34. Supplementary Figure 8 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
35. Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
36. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
37. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
38. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
39. Supplementary Figure from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
40. Supplementary Data from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
41. Supplementary Figure from Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
42. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
43. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer
44. Abstract P1-07-02: Mesenchymal stem cell regulated microRNAs converge on the speech gene FOXP2 and regulate breast cancer metastasis
45. Abstract 173: Tumor proximal mesenchymal stem cells initiate a pro-metastatic microRNA regulatory network which acts via convergent targeting of the speech-associated transcriptional repressor FOXP2
46. Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
47. Abstract 1150: Biomarkers discovery and racial disparity in hepatitis C-associated hepatocellular carcinoma.
48. Abstract LB-313: ALK1-Fc inhibits tumor growth in a VEGF pathway resistance model of renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.